I-01
|
|
4‐({6‐[(3‐bromophenyl) amino]‐[1,2,5] oxadiazolo [3,4‐b] pyrazin‐5‐yl} amino) phenol
|
4,76 %, (p < 0.05)
|
I-02
|
|
(4E)‐1‐(3,4‐dichlorophenyl)‐4‐[(4‐hydroxy‐3‐iodo‐5‐methoxyphenyl) methylidene]‐3‐methyl‐4,5‐dihydro‐1H‐pyrazol‐5‐one
|
6,40 %, (p < 0.05)
|
I-03
|
|
(5E)-5-[(4-fluorophenyl) methylidene]-3-[(4-iodoanilino) methyl]-1,3-thiazolidine-2,4-dione
|
7,10 %, (p < 0.05)
|
I-04
|
|
2‐(4‐{[(2Z,5Z)‐4‐oxo‐3‐phenyl‐2‐(phenylimino)‐1,3‐thiazolidin‐5‐ylidene] methyl} phenoxy) acetic acid
|
7,36 %, (p < 0.05)
|
I-05
|
|
ethyl 4-[3-[(3-bromophenyl) methyl]-4-oxo-2-sulfanylidene-1H-quinazoline-7-carbonyl] piperazine-1-carboxylate
|
8,96 %, (p < 0.05)
|
I-06
|
|
3,4-dihydro-2H-quinolin-1-yl-[3-(4-phenylpiperazin-1-yl) sulfonylphenyl] methanone
|
9,60 %, (p < 0.05)
|
I-07
|
|
2-chloro-5-[(4Z)-4-[(3-methoxy-4-phenylmethoxyphenyl) methylidene]-3-methyl-5-oxopyrazol-1-yl] benzoic acid
|
9,92 %, (p < 0.05)
|
I-08
|
|
(4Z)-4-[(2-methoxy-1-naphthyl) methylene]-2-(4-methoxy-3-nitrophenyl)-1,3-oxazol-5 (4H)-one
|
11,52 %, (p < 0.05)
|
I-09
|
|
4-[(4E)-4-[(4,5-dimethoxy-2-nitrophenyl) methylidene]-3-methyl-5-oxopyrazol-1-yl] benzoic acid
|
12,16 %, (p < 0.05)
|
I-10
|
|
N-[(5Z)-5-[(3,4-dimethoxyphenyl) methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-nitrobenzamide
|
14,19 %, (p < 0.05)
|
I-11
|
|
(4E)-2-(3,4-dichlorophenyl)-4-[(3,4-dimethoxyphenyl) methylidene]-5-methylpyrazol-3-one
|
14,41 %, (p < 0.05)
|
I-12
|
|
2-phenylethyl 7-(4-chlorophenyl)-4-(4-hydroxy-3-methoxyphenyl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylate
|
16,33 %, (p < 0.05)
|
I-13
|
|
4-[[2-bromo-4-[(2,4,6-trioxo-1,3-diazinan-5-ylidene) methyl] phenoxy] methyl] benzoic acid
|
16,97 %, (p < 0.05)
|
I-14
|
|
methyl 4-[[(5E)-5-[(4-methylsulfanylphenyl) methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl] methylamino] benzoate
|
17,70 %, (p < 0.05)
|
I-15
|
|
4-[4-(dimethylamino) phenyl]-8-{(E)-1-[4-(dimethylamino) phenyl] methylidene}-3,4,5,6,7,8-hexahydro-2 (1H)-quinazolinethione
|
19,74 %, (p < 0.05)
|
I-16
|
|
[3-(1,3-benzodioxol-5-yl)-2-methyl-4-oxo-6-propylchromen-7-yl] acetate
|
27,09 %, (p < 0.05)
|
I-17
|
|
2-(7,7-dimethyl-3-oxobicyclo [2.2.1] hept-2-yliden)-N-(4-methylphenyl)-1-hydrazinecarbothioamide
|
29,82 %, (p < 0.05)
|
I-18
|
|
2-(9H-xanthen-9-yl)-1H-indene-1,3 (2H)-dione
|
48,49 %, (p < 0.05)
|
I-19
|
|
2-{4-[(isopentyloxy) carbonyl] phenyl}-1,3-dioxo-5-isoindolinecarboxylic acid
|
49,20 %, (p < 0.05)
|
S-01
|
|
4-[bis (2-methoxyethyl) sulfamoyl]-N-[4-(4-nitrophenyl)-1,3-thiazol-2-yl] benzamide
|
119,09 %, (p < 0.05)
|
S-02
|
|
(3-Chloro-1-benzothiophen-2-yl) (10,11-dihydro-5H-dibenzo [b,f] azepin-5-yl) methanone
|
126,24 %, (p < 0.05)
|
S-03
|
|
N-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-2-phenoxybenzamide
|
129,23 %, (p < 0.05)
|